
MIRZYME AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA
MIRZYME THERAPEUTICS AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA FROM THE MHRA, THE UK REGULATOR...
MIRZYME AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA
CEO Nominated for Businessman of The Year
Women’s Health Innovation Summit - Boston, USA
U.K. policy report sets out a vision to incentivise industry to develop pregnancy-specific medicines
ONE PILL WONDER – MirZyme Therapeutics on AIMDay at Oxford University
Women's Health Strategy: Call for Evidence
COVID-19 leads to preeclampsia and poor pregnancy outcomes
Saving the Lives of Mothers and Babies - Webinar
Two breakthrough studies show a hydrogen sulfide drug prevents preeclampsia
MirZyme Therapeutics partners with King Abdulaziz University
Scientists at MirZyme have developed a breakthrough ‘miracle’ cure for preeclampsia
Europe’s New Roadmap for a Healthier Pregnancy
The statin that saves babies from stillbirth
Breakthrough in fight against pre-eclampsia: Scientists may have found cause of the life-threatening